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Beneficial effects of systemic immunoglobulin in experimental membra-
nous nephropathy. To test the hypothesis that systemic administration of
immunoglobulin might reduce glomerular injury in membranous nephrop-
athy through mechanisms involving inhibition of complement activation,
we studied the passive Heymann nephritis (PHN) model of membranous
nephropathy in rats. The daily administration of immunoglobulin goat IgO
(600 mg/kg i.p.) reduced proteinuria by 52%. Quantitative immunohisto-
chemical analysis showed that the glomerular deposition of C3c, an
indicator of ongoing complement attack, and of C5b-9 was significantly
decreased in the immunoglobulin treated group, while deposition of
anti-Fx1A was not affected. Electron microscopic analysis demonstrated
that the extent of subepithelial immune complexes did not appreciably
differ between treated and control animals. Systemic complement levels
were not altered by immunoglobulin treatment. These data suggest that
the reduction in proteinuria that resulted from systemic immunoglobulin
administration was mediated by modiiing the effect of complement
induced glomerular injury. This interpretation was further supported by in
vitro data that documented a significant reduction in C5b-9 induced
glomerular epithelial cell lysis in the presence of both goat and rat IgG.
These results indicate that systemic administration of immunoglobulin can
substantially reduce ongoing complement activation in the glomerulus in
PuN rats and that this effect is associated with a significant reduction in
glomerular injury.
Membranous nephropathy (MN) is a common cause of idio-
pathic nephrotic syndrome in adults [1, 21. Many patients with MN
progress to renal failure [3—61. Treatment of MN remains con-
troversial [7—9]. Several studies have shown no benefit from
conventional steroid and immunosuppressive agents [10—131.
Other investigators have reported modest success with regimens
employing alternating monthly cycles of intravenous steroids and
chlorambueil [14], but toxicity is significant, particularly in pa-
tients with impaired renal function [151.
Glomerular injury in MN is believed to be a complement-
mediated process because of the remarkable similarity between
the functional and immunopathologic features of MN in humans
and those of the Heymann nephritis models in rats [16—181. In
passive Heymann nephritis (PHN), suhepithelial deposits occur as
a consequence of antibody binding to antigens expressed on the
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surface of the glomerular epithelial cell (GEC), and proteinuria
results from GEC membrane insertion of the C5b-9 membrane
attack complex of complement [17, 19, 201. Similar mechanisms
may be operative in humans as well [161.
Considerable evidence has now accumulated that intravenous
immunoglobulin (IVIG) has beneficial effects on a variety of
antibody-mediated diseases in humans including lupus nephritis,
IgA nephropathy and ANCA-positive vasculitis [21—23]. In one
study, IVIG reduced proteinuria and improved renal function in
patients with MN resistant to other therapies [241. The mecha-
nism by which IVIG exerts a beneficial effect in these diseases is
unknown, although most authors have suggested an effect on the
immune response probably through idiotype—anti-idiotype inter-
actions [25—271. However, recent studies demonstrate that IVIG is
also a potent inhibitor of complement activation through direct
binding to C3 and C4 activation products [28—31]. Based on these
observations, we postulated that systemic administration of im-
munoglobulin (SIG) might he an effective therapy in MN because
of its complement inhibitory properties. We tested this hypothesis
in the PHN model of MN in rats where the passive administration
of nephritogenic antibody precludes any influence of systemic
immunoglobulin on the immune response, and no mediators of
glomerular injury other than complement have been identified.
The results indicate that SIG does substantially reduce evidence
of ongoing complement activation in the glomerulus and that this
effect is associated with a significant reduction in glomerular
injury as measured by urine protein excretion.
Methods
Induction of passive Heymann nephritis and experimental design
The passive Heymann nephritis (PHN) model was induced in
250 g male Sprague-Dawley rats (N = 12) (Simonsen Laborato-
ries) by the injection of 0.9 ml of sheep anti-rat FxlA antiserum as
described previously [32, 33]. The injection of nephritogenic
antiserum was performed two hours after the initial injection of
high dose IgG or vehicle only. An experimental group of 6 rats
was treated with IgG, 600 mg/kg i.p., administered two hours
before anti-Fx1A antibody injection and 24, 48, and 72 hours later.
A control group received the same dose of anti-FxIA but was
treated with vehicle.
Urine protein excretion was measured from days 4 to 5 after the
antibody injection using the sulfosalicylic acid method [34], at
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Renal tissue was embedded in O.C.T., snap-frozen in liquid
nitrogcn cooled isopentanc, and stored at —70°C until processed.
Four micron cryostat sections were cut and fixed with 1:1 ethanol!
ether. Sections were stained with FITC-conjugatcd goat anti-rat
C3 (Cappel) which reacts primarily with rat C3c [38], biotinylated
monoclonal antibody to a neoantigen of rat C5b-9 (2A1), or goat
anti-sheep IgG (Cappel).
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Fig. 1. CR8 staining of purified JgG. Thirty jsg of purified IgG was
elecirophoresed with 15% SDS-PA GE gel and was stained with coomassie
brilliant blue, which demonstrated high purity of the protein.
which time the animals were sacrificed and renal biopsies were
obtained for examination by light microscopy, immunofluores-
cence, and electron microscopy. All animal studies were per-
formed in an accredited animal care facility in accord with the
NIH guide lines for the Care and Use of Laboratory Animals.
Preparation of !gG
Goat plasma was purchased from J.J.J. Farms (Redmond, WA,
USA). Rat serum was purchased from Sigma (St. Louis, MO,
USA). IgG was purified utilizing a caprylic acid precipitation
method [35]. After adjusting the pH of the plasma to 5.5 with HCI,
5.5 ml!100 ml plasma of caprylic acid solution (Sigma) was added
dropwise with vigorous stirring. Then the solution was stirred for
one hour at room temperature and centrifuged at 14K rpm for 30
minutes at room temperature. The supernatant was collected and
dialyzed against water which was adjusted with HCI to pH 4.2 in
order to enhance its monomer content and stability [361. The
dialyzed solution was centrifuged at 14K rpm for 30 minutes at
4°C. This supernatant was sterilized by filtration and stored at 4°C.
If necessary, TgG solution was concentrated utilizing ccntri-plus
(Amicon, Beverly, MA, USA). Purity of the prepared IgG was
confirmed by Coomassie brilliant blue staining of 15% SDS-
PAGE gel (Fig. 1).
Measurement of goat IgG in serum
Serum levels of goat lgG were measured by radial immunodif-
fusion (RID) [371 two hours after the injection and 24, 48, 72, 96,
and 120 hours later. Briefly, 1.5% agarose in 0.5 M vcronal buffer
containing a 1:50 dilution of rabbit anti-goat IgG (Cappel,
Durham, NC, USA) was poured, and after cooling 2 mm holes
were punched. Then 3 l of goat IgG standards at 5, 2.5, 1.25,
0.625, or 0.313 mg/mI as well as 3 il of rat plasma at specific time
points were added. The diameters of the rings from precipitation
of goat IgG in the plasma samples by the antibody were read off
of the curve generated by the diameters of the rings from the
known standards.
Quantification of glomenslar deposits of antibody and complement
by laser scanning confocal microscopy
To examine an effect of SIG on glomerular antibody deposition,
ACAS Ultima Interactive Laser (ytometer (Meridian Instru-
ments, Okemos, MI, USA) was utilized for quantitative analysis of
immunofluorescence intensity as previously described [391.
Briefly, 4 jim sections of frozen kidney were stained as described
above and were then scanned. An image field of 3.2 mm2 was
scanned for each section; where less than 15 glomeruli were
present, two fields were scanned. Using the Meridian image
analysis system, the fluorescence intensity of individual glomeruli
was then measured. Two different sections (containing a total of
--—14 to ——52 glomeruli) from each rat were analyzed, and more
than 250 glomeruli were measured for each experiment.
Electron microscopy
Tissue for electron microscopy (EM) was fixed in half-strength
Karnovsky's solution (1% paraformaldehyde and 1.25% glutaral-
dchydc in 0.1 M Na cacodylatc buffer, pH 7.0), postfixed in
osmium tetroxide, dehydrated in graded ethanols, and embedded
in epoxy resin. Thin sections were stained with uranyl acetate and
lead citrate and examined with a Philips 410 (Philips Export By,
Eindhoven, The Netherlands) electron microscope.
Serum C3, CH5O, and BUN measurement
To examine the effect of SIG on serum complement levels, C3
was measured using the radial immunodiftusion method as de-
scribed above using goat anti-rat C3 (Cappel).
The hemolytic activity of complement in SIG and vehicle
treated serum was measured by the hemolysis of sheep erythro-
cytes sensitized by specific antibodies (anti-sheep hemolysin) and
compared to serum taken from the rats prior to therapy [40]. The
degree of hemolysis is expressed in CH5O units. One CH5O unit is
defined as the volume of serum that will lyse 50% of the
erythrocytcs in the reaction mixture. The number of CH5O units in
1 ml of serum is the hemolytic titer.
BUN was determined colorimetrically utilizing a commercial kit
for the measurement of urea nitrogen (Sigma Diagnostics).
Urinary C5b-9 measurement
Urine was collected overnight (days 4 to 5) into a concentrated
mixture of protease inhibitors and rat C5b-9 was assayed using an
enzyme-linked immunoabsorbent assay as reported previously
[32, 38, 41]. Briefly, a monoclonal antibody to a neoantigen of rat
C5b-9 (2A1) was employed as a capturing antibody, while a
biotinylated polyclonal antibody to human Co (Calbiochem, San
Diego, CA, USA) was used as a detecting antibody. C5b-9 units
were calculated using a previously defined inulin-activated rat
serum reference standard.
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Studies of GEC in culture
To further examine the effect of IgG on C5b-9 mediated injury
to the GEC, a rat glomerular epithelial cell line was established
and maintained as previously described [42]. After the 20th
passage on collagen matrix (Vitrogen Collagen, Palo Alto, CA,
USA), cells were grown on 100-mm tissue culture dishes coated
with bovine type I collagen (Collaborative Research, Bedford,
MA, USA). They were maintained in K-i medium supplemented
with 2% NuSerum (Collaborative Research) at final concentra-
tions of 5 jg/ml insulin, 5 jig/mI transferrin, and 5 nglml selenium
(Collaborative Research). The characterization to confirm that
this cell line represents glomerular epithelial cells was performed
as described previously [43]. Cultured cells exhibited characteris-
tics typical of GEC with positive staining for anti-Fx1A and
negative staining for a-smooth muscle actin, Thy 1.1, and factor
VIII.
Complement-mediated cell lysis assay
Complement-mediated GEC lysis assays were performed as
previously described [44]. Briefly, GEC were passaged into 24-
well plates and grown until subconfluent. After washing with
veronal buffered saline (VBS), the cells were sensitized with 3
mg/mI of anti-Fx1A for 30 minutes at room temperature. Follow-
ing further washing, the cells were incubated with 10% normal rat
serum in DMEM as a complement source and various concentra-
tions of rat IgG for 90 minutes at 37°C. Similar studies were also
done with goat IgG. Cell lysis was quantitated by a lactate
dehydrogenase (LDH) assay (Sigma Diagnostics) from superna-
tants of treated cells. After the assay, all cells were then lysed with
2% Triton X-iOO, and complement-mediated cell lysis was calcu-
lated as the lysis induced by antibody and complement divided by
the lysis induced by Triton X-100 multiplied by 100.
Statistics
All results are presented as mean SD. Significance was
assessed by ANOVA-repeated measures.
Results
Serum level of goat IgG after the treatment
To document that elevated levels of goat lgG in serum were
achieved following i.p. injection, we measured serum levels of goat
IgG by RID. Two hours after SIG treatment, the serum concen-
tration of goat IgG increased to 4.03 0.39 mg/ml. Serum levels
of goat lgG were maintained between 3.5 and 5.0 mg/mI through-
out the experimental period.
Proteinuria was attenuated by SIG
Before the induction of PHN, both control and IgG-treated rats
showed normal amount of urinary protein excretion (8.0 4.2
and 6.5 2.8 mg/24 hr, respectively). At day 5 of PHN, urinary
protein excretion of control rats was 60.6 26.1 mg/24 hr.
However, IgG treatment significantly reduced proteinuria to
29.3 24.0 mg/24 hr (P < 0.05).
Immunohistochemical analysis
To investigate the mechanism by which SIG reduced protein-
uria, we performed immunohistochemical studies. First, we deter-
mined if there was a difference in the amount or distribution of
anti-Fx1A antibody deposition between control and IgG-treated
rats. As shown in Figure 2A, the anti-Fx1A binding to the
glomerulus was equal in control and IgG-treated rats. Quantifi-
cation by confocal microscopy demonstrated 2770 93 average
fluorescence units per area in control and 2929 136 in IgG-
treated rats. Therefore, the beneficial effect of IgG did not result
from decreased pathogenic antibody deposition.
We then analyzed deposition of complement components in the
glomerulus. We have previously shown that C3c staining is an
indicator of ongoing complement attack because it is transient
and detectable only during active complement activation and
deposition in this model [38]. Staining for C3c was significantly
decreased in the IgG-treated group compared with controls
(1569 220 fluorescence units per area vs. 2171 526, P < 0.05;
Fig. 2B). These data are consistent with the hypothesis that SIG
administration caused a reduction in ongoing complement depo-
sition.
To confirm this hypothesis, we performed quantitative immu-
nofluorescence study of glomerular C5b-9 staining. Staining for
C5b-9 was also significantly decreased in the IgG treated group
compared with controls (1201 360 fluorescence units per area
vs. 1838 395, P < 0.05; Fig. 2C).
Electron microscopy
Ultrastructural examination was performed on biopsies from
four animals (2 representative animals from the vehicle treated
control group, and 2 representative animals from the SIG treated
group). Each animal examined demonstrated numerous, discrete
electron dense deposits confined to subepithelial portions of the
peripheral glomerular capillary walls (Fig. 3). No differences in
amount, size, distribution, or granular appearance of these depos-
its were detectable amongst any of the animals examined. Foot
process effacement in pedicles overlying these electron dense
deposits was uniform in all animals.
There was a trend towards better preservation of individual foot
processes in those portions of the glomerular capillaries without
immune deposits in the animals with lesser degrees of proteinuria,
but this trend was not uniform amongst all capillary loops
examined. No other abnormalities of glomerular, tubular, or
interstitial structure were identified in animals of either group.
Urinary C5b-9 measurement
We have previously shown that urinary C5b-9 excretion reflects
active glomerular immune deposit formation in PHN [321. To
confirm attenuation of complement mediated glomerular injury
by SIG administration, we measured urinary C5b-9 excretion of
both control and IgG-treated animals. IgG-treated rats demon-
strated lower C5b-9 excretion compared with control animals with
a marginal significance (2.23 0.22 units/24 hr vs. 4.54 2.02,
P = 0.06).
Complement status in treated rats
To examine if SIG affected systemic complement levels, we
measured serum C3 and CH5O levels throughout the experimental
period. As shown in Figure 4, there was no evidence of systemic
complement activation and no significant difference between
control and IgG-treated rats.
Renal function in treated rats
The deterioration of renal function in SIG treated rats might
cause the reduction of the total protein excreted into urine. To
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Fig. 2. Immunofluorescent photographs of
representative glomeruli in control (left panels)
and IgG treated (right panels) rats with PHN at
day 5. Tissues were stained for sheep IgG (A),
rat C3c (B), and C5b-9 (C). Deposition of lgG
is similar in both groups, but C3c and C5b-9
staining is reduced in the IgG treated animal
(magnification ><40).
confirm that intact function was similar in both groups, we In vitro studies
measured BUN at day 5. There was no significant difference in To confirm that goat IgG can attenuate anti-FxIA antibody and
BUN levels between lgG-treatcd and control rats (23.7 4.9 complement-induced GEC injury, we performed complement-
mg/dl vs. 20,4 3.0, P> 0.05). mediated cell lysis assays utilizing cultured GEC. Cultured GEC
1 
0 
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Fig. 3. Ultrastructural appearance of glomeruli from control rats (A) and SIG treated rats (B) (magnification )< 17750). Numerous subepithelial immune
deposits are present in the capillary walls of both, with similar effacement of epithelial cell foot processes overlying the deposits.
were sensitized with 3 mg/mI anti-Fx1A, followed by incubation
with 10% of normal rat serum as the complement source.
Complement-induced GEC lysis was expressed as a % of total cell
lysis achieved with Triton X-100. At 10 mg/mI goat IgO, cell lysis
occurred without statistically significant difference in both cells
treated with IgG and controls (37.0 12.9% and 50.5 5.0%,
respectively, N = 4). However, when 20 mg!ml goat IgG was
added, cell lysis was significantly inhibited in the IgG-treated
group (16.5 10.6%, N = 4, P < 0.01; Fig. 5).
We also investigated the effects of homologous IgG on com-
plement-induced GEC injury. Purity of the rat IgG preparation
was confirmed by coomassie brilliant blue staining of SDS-PAGE
(Fig. 1). Purified rat IgG demonstrated a remarkably protective
effects on GEC at 10 mg/mI compared with cells treated with 5
mg/mI of IgG and controls (4.8 6.2%, 31.8 6.3%, and 47.2
11.2%, respectively, N = 5, P < 0.01; Fig. 5).
Discussion
Since the initial observation in 1981 that patients with idio-
pathic thrombocytopenic purpura showed a marked improvement
in response to high-dose IVIG [45], IVIG has been used as a
therapeutic agent in the treatment of some autoimmune diseases
including thrombocytopenic purpura, Kawasaki disease, and my-
asthenia gravis. The therapeutic effects of IVIG have been
attributed to various mechanisms including the blocking of Fe
receptors and anti-idiotype inhibition of pathogenic Ig [25—27, 46,
47]. IVIG has also been reported to be effective in various renal
diseases, including lupus nephritis [22], antineutrophil cytoplas-
mic antibody nephritis [21], hemolytic uremic syndrome [48], type
II membranoproliferative glomerulonephritis [49], and severe IgA
nephropathy [23]. In addition, preliminary trials of IVIG in
patients with idiopathic MN have shown some benefit. The
authors speculated that the mechanisms of action of IgG might be
dissociation of subepithelial immune complex deposits or inhibi-
tion of an anti-idiotypic antibody response [24].
However, in addition to the possible beneficial effects of IVIG
described above, it has recently been pointed Out that Ig may also
regulate the complement cascade by preventing the binding of
activated C3 to antibody-coated targets [30, 311. In both MN and
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Fig. 4. Systemic complement status of the rats. No significant differences
were detected in serum C3 (A) and CH5O (B) levels between control (0)
and IgG-trcated (A) rats.
IgA nephropathy treated with IVIG, decreased C3 deposition in
glomeruli has been observed [23, 241. Here we report improve-
ment of PHN by S1G through an apparent complement modifying
mechanism. The dose of IgG we injected (600 mg/kg) was
equivalent to that used in therapeutic studies in humans (400 to
2000 mg/kg) [25], The intraperitoneal route was chosen for
injection because the volume of IgG solution was too great for
intravenous injection. It has previously been shown that levels of
IgG in the plasma of rodents are similar when IgG is administered
by intravenous or intraperitoneal routes [50]. SIG treatment did
not alter glomerular antibody deposition but did reduce protein-
lgG, mg/mi
Fig. 5. Effects of IgG on complement mediated cell lysis of cultured GEC.
Cultured GEC sensitized with anti-Fx1A were incubated with rat comple-
ment. A total of 20 mg/mI of goat lgG (A) inhibited complement-mediated
cell lysis of cultured GEC. Furthermore, homologous rat IgG (0) showed
much stronger inhibitory effect on GEC lysis even at a lower
concentration.
uria by over 50%. This was accompanied by reduction in glomer-
ular staining for C5b-9 and C3c, an index of ongoing complement
activation, and reduced urinary C5b-9 excretion.
Complement activation mediates immune glomerular injury
through several mechanisms including localization of circulating
inflammatory cells through generation of ehemotactic factors and
immune adherence mechanisms and direct injury to resident
glomerular cells through membrane insertion of the membrane
attack complex, C5b-9 [51, 52]. The role of C5h-9 in mediating
changes in glomerular permeability has been particularly well
established in models of MN induced by passive administration of
antibody to antigens on the membrane of GEC (PHN) [20, 33,
531.
SIG might attenuate complement-mediated tissue injury
through several mechanisms. First, the IgG preparation by itself
might activate and deplete complement. This mechanism is
unlikely in our study because measurement of circulatory C3 and
CH5O demonstrated no difference between control and IgG-
treated animals. Second, interference with the deposition of
anti-Fx1A in glomeruli might also occur by accelerating antibody
clearance or reducing glomerular delivery. However, our quanti-
tative immunohistochemical analysis and electron microscopic
study demonstrated no differences in antibody deposition or
immune complex formation between SIG treated and control
animals. Third, immunoglobulin can prevent complement activa-
tion by binding to C3 and C4 to prevent its interaction with cell
membranes. Our observation of a decrease in C3c deposition
without any change in the plasma level of C3, a finding also
reported by others [30], supports this mechanism.
IgG is known to he an efficient acceptor for C3 and C4
fragments including C3b [54—57]. High levels of fluid-phase IgG
have been shown to compete directly for nascent C3b [58].
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Therefore supraphysiologic amounts of lgG may divert C3b from
target membranes and suppress complement-mediated disease.
High-dose immunoglobulin has been shown to have a beneficial
effect on the Forssman shock model [311 and xenotransplantation
[28, 29] by modulating complement-mediated tissue injury. We
believe that systemic immunoglobulin therapy reduced protein-
uria in PHN in our study by the same complement modifying
mechanism.
Although we did not completely abolish urinary protein excre-
tion with systemic immunoglobulin as is usually achieved with
complement depletion with cobra venom factor [59], the reduc-
tion in proteinuria (52%) was greater than that achieved by
recombinant complement receptor 1 treatment in the same model
(37% reduction) [60].
Our hypothesis that the reduction in proteinuria in SIG treated
group was mediated by modifying the effect of complement
induced injury is supported by the finding that the glomerular
deposition of C3c was decreased in SIG treated rats. Activation of
C3 occurs as the result of proteolysis. The cleavage produces a
small polypeptide, anaphylatoxin C3a, and activated C3b, which
binds to the target surface and initiates C5b-9 assembly. C3b is
further degraded into "c" and "d" fragments. The C3c fragment is
rapidly released from the binding site, whereas C3d remains
covalently attached to target membranes [61—641. Utilizing these
characteristics of C3c and C3d, we have previously shown that
positive staining for C3c documents on-going complement activa-
tion in the glomerulus, while C3d deposits persist despite lack of
ongoing complement activity and do not closely parallel disease
activity [38]. Therefore our quantitative immunohistochemical
data suggest that ongoing complement activation in glomeruli is
suppressed by SIG treatment. This conclusion is also supported by
the decrease in glomerular staining for C5b-9 and the greater than
50% reduction in urinary C5b-9 in SIG treated animals, although
the latter result did not reach statistical significance.
The conclusion that IgG can modulate C5b-9 induced GEC
injury is further supported by in vitro data which document a
significant reduction in C5b-9 induced GEC lysis in the presence
of IgG. Goat IgG demonstrated protective effects on comple-
ment-mediated GEC lysis at the concentration of 20 mg/ml. While
this concentration exceeds that achieved in vivo, it is likely that the
amounts of C5b-9 inserted into GEC in vivo, where lysis is usually
not seen, is substantially less than that achieved in vitro and
probably suppressible at lower IgG concentration. Moreover, the
pathogenic effect of C5b-9 in vivo is believed to reflect sublytic
effects of C5b-9 on the GEC leading to production by the cell of
inflammatory mediators such as oxidants and proteases [51,
65—691, effects which occur with much smaller amounts of mem-
brane-inserted C5b-9 than those required to produce cell lysis.
Moreover, we also found that homologous rat IgG was more
effective than goat lgG in protection of GEC from complement-
mediated cell lysis in vitro with significant protection produced at
concentrations of only 10 mglml.
In conclusion, SIG significantly ameliorated glomerular injury
in PHN as documented by a greater than 50% reduction in urine
protein excretion. The reduction in glomerular C3c and C5b-9
deposition as well as urinary C5b-9 excretion suggest that this
effect was consequent to a reduction in complement activation by
SIG. SIG deserves more formal evaluation as a potential thera-
peutic tool in complement-mediated immune glomerular disease
in humans.
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